By Sabela Ojea 



  AstraZeneca PLC said Wednesday that its Lynparza medicine has been approved in the European Union for patients diagnosed with germline BRCA-mutated metastatic pancreatic cancer, one of the most common cancers with the lowest survival rate. 


  The pharmaceutical giant said the approval was based on results from the Phase 3 Polo trial. 


  Only around 5% to 7% of these patients with metastatic pancreatic cancer have a germline BRCA mutation, the London-listed company said. 


  "Lynparza is approved in the U.S. and several other countries as a 1st-line maintenance treatment for patients with gBRCAm metastatic pancreatic cancer based on the Phase 3 Polo trial , with ongoing regulatory reviews in other regions," AstraZeneca said. 


  Write to Sabela Ojea at sabela.ojea@wsj.com; @sabelaojeaguix